Markets News

Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.

Long-Dated UK Yields Steady Near Heights as Fiscal Worries Persist
Markets Daniel Marsh

Long-Dated UK Yields Steady Near Heights as Fiscal Worries Persist

UK 30-year gilt yields remain near record highs as fiscal and inflation worries persist. The 10-year yield surpasses year-end survey projections, with BoE meeting and budget due.

EWU GLD USO UNG
Opendoor Gains 1.6% as Inventory Swells to $1.85B Amid Rate Uncertainty
Markets Daniel Marsh

Opendoor Gains 1.6% as Inventory Swells to $1.85B Amid Rate Uncertainty

Opendoor (NASDAQ:OPEN) gained 1.6% to $3.09 as its $1.85 billion inventory underscores interest-rate exposure. Q2 purchases surged 149% while sales fell 46%.

OPEN ZG OPAD
Broadcom Forecast Misses, Tech Futures Flat, Oil Dips
Markets Daniel Marsh

Broadcom Forecast Misses, Tech Futures Flat, Oil Dips

Broadcom's softer forecast weighs on tech futures, while oil prices ease. S&P 500 and Nasdaq futures hold steady, gold rises 1.29%.

AVGO SNOW HPE DELL NVDA USO GLD
Air Canada Shares Dip Below Buyback Floor as Jazz Crews Vote on Strike
Markets Daniel Marsh

Air Canada Shares Dip Below Buyback Floor as Jazz Crews Vote on Strike

Air Canada shares slipped below its buyback threshold as Jazz Aviation flight attendants vote on a strike mandate, threatening regional operations.

CNH Surges 9% on Upgrade, Farm Rebound Seen by 2027
Markets Daniel Marsh

CNH Surges 9% on Upgrade, Farm Rebound Seen by 2027

CNH Industrial shares surged 9.2% after Evercore ISI upgraded the stock and raised its price target to $18, citing an anticipated farm equipment rebound by 2027.

CNH DE
Ultragenyx Plunges 44% as Angelman Gene Therapy Fails Phase 3 Trial
Markets Daniel Marsh

Ultragenyx Plunges 44% as Angelman Gene Therapy Fails Phase 3 Trial

Ultragenyx's stock plummeted 44% after its Phase 3 apazunersen trial failed, wiping out $1.14 billion in market cap. The company now faces major cost cuts.

RARE
PG&E Shares Tumble 5% on $2B Capex Cut Amid Regulatory Uncertainty
Markets Daniel Marsh

PG&E Shares Tumble 5% on $2B Capex Cut Amid Regulatory Uncertainty

PG&E shares dropped 5.2% after the utility postponed $2 billion in 2027 capital spending, citing financing costs and regulatory uncertainty. The company reaffirmed 2026 guidance but trimmed expansion plans.

PCG EIX SRE XLU
Small Caps Lead Market Rebound as Wall Street Breaks Losing Streak
Markets Daniel Marsh

Small Caps Lead Market Rebound as Wall Street Breaks Losing Streak

Wall Street rebounded Wednesday, ending a three-day losing streak. The Russell 2000 led gains, rising 1.1%, while Snowflake surged 22% in after-hours trading.

SPY QQQ IWM SNOW NTAP HPE AVGO DELL NVDA PANW CRDO XLB XLF XLV XLE XLRE XLK
Live Nation Rises 1.3% as Venue Expansion Tests Margin Strategy
Markets Daniel Marsh

Live Nation Rises 1.3% as Venue Expansion Tests Margin Strategy

Live Nation shares rose 1.3% as new venue openings test margin mix, with Q2 revenue up 9% and ticketing AOI up 14%.

LYV
Small Caps Lead Wall Street Rebound as Three-Day Slide Ends
Markets Daniel Marsh

Small Caps Lead Wall Street Rebound as Three-Day Slide Ends

Wall Street snapped a three-day losing streak, led by small caps. The Russell 2000 jumped 1.13%, while Dell and Snowflake surged on strong results.

NVDA PANW DELL SNOW AVGO SPY QQQ DIA IWM
Small Caps Lead Wall Street Rebound, But Market Internals Stay Weak
Markets Daniel Marsh

Small Caps Lead Wall Street Rebound, But Market Internals Stay Weak

The Russell 2000 climbed 1.13% on Wednesday, leading a broad market rebound, yet new lows continued to outpace highs. Dell surged on strong guidance, while ADP data showed sluggish hiring.

DELL NVDA MU PANW IWM SPY QQQ DIA
Chevron Advances in Venezuela With $7B Plan to Boost Output to 600,000 bpd
Markets Daniel Marsh

Chevron Advances in Venezuela With $7B Plan to Boost Output to 600,000 bpd

Chevron (CVX) shares gained 0.58% to $212.28 after announcing a $7B Venezuela expansion targeting 600,000 bpd, but investor skepticism persists over political stability.

CVX